PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29283216-0	2018	A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.	Bleomycin	106-115	vascular endothelial growth factor A	Mus musculus	67-71	
29283216-3	2018	EXPERIMENTAL DESIGN: The authors have used shotgun lipidomics in a bleomycin (BLM) mouse model of pulmonary fibrosis with vascular endothelial growth factor (VEGF)-inhibitor CBO-P11 as a therapeutic measure, to identify a comprehensive set of lipids that contribute to the pathogenesis of pulmonary fibrosis.	Bleomycin	67-76	vascular endothelial growth factor A	Mus musculus	158-162	
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	90-99	vascular endothelial growth factor A	Mus musculus	32-36	
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	143-152	vascular endothelial growth factor A	Mus musculus	32-36	
28814671-5	2017	Lung-specific overexpression of VEGF significantly protected mice following intratracheal bleomycin challenge, with a decrease in fibrosis and bleomycin-induced cell death observed in the VEGF transgenic mice.	Bleomycin	143-152	vascular endothelial growth factor A	Mus musculus	188-192	
23918036-6	2014	In the proinflammatory bleomycin model, the profibrotic effect became more pronounced with induction of skin fibrosis in VEGF+/- tg mice and even more enhanced fibrosis in VEGF+/+ tg mice.	Bleomycin	23-32	vascular endothelial growth factor A	Mus musculus	121-125	
23918036-6	2014	In the proinflammatory bleomycin model, the profibrotic effect became more pronounced with induction of skin fibrosis in VEGF+/- tg mice and even more enhanced fibrosis in VEGF+/+ tg mice.	Bleomycin	23-32	vascular endothelial growth factor A	Mus musculus	172-176	
22691970-5	2012	METHODS: Effect of a mouse anti-VEGF antibody was monitored on acute toxicity studying radiation-induced intestinal ulceration (12 Gy TBI); on subacute toxicity using a model of oral mucositis (16.5 Gy); on late radiation injuries by monitoring lung fibrosis (bleomycin and 19 Gy).	Bleomycin	260-269	vascular endothelial growth factor A	Mus musculus	32-36	
22691970-6	2012	RESULTS: Combination of irradiation with anti-VEGF antibody enhanced intestinal damages with severe epithelial ulcerations, had no adverse impact on oral mucositis and dramatically worsened the fibrotic picture induced by bleomycin and irradiation to the lung.	Bleomycin	222-231	vascular endothelial growth factor A	Mus musculus	46-50	
18976720-3	2009	The aim of the present study was to assess whether disruption of VEGF pathway would attenuate bleomycin-induced pulmonary fibrosis.	Bleomycin	94-103	vascular endothelial growth factor A	Mus musculus	65-69	
18976720-4	2009	METHODS: Bleomycin-induced pulmonary fibrosis mice were treated intraperitoneally with VEGF receptor tyrosine kinase inhibitor SU5416 at different phases after bleomycin infusion.	Bleomycin	9-18	vascular endothelial growth factor A	Mus musculus	87-91	
31176171-0	2019	The role of vascular endothelial growth factor receptor 1 tyrosine kinase signaling in bleomycin-induced pulmonary fibrosis.	Bleomycin	87-96	vascular endothelial growth factor A	Mus musculus	12-46	
26322414-5	2015	We hypothesized that loss of EC-SOD would worsen PAH associated with BPD in a neonatal mouse model of bleomycin-induced BPD by disrupting the VEGF/NO signaling pathway.	Bleomycin	102-111	vascular endothelial growth factor A	Mus musculus	142-146